Mar 10,2022

HelloBetter scores €10 million in Series A round

Berlin-based, digital therapeutics firm HelloBetter has announced a €4 million extension of its €6 million Series A funding round, bringing the total investment round to €10 million. MassMutual Ventures (MMV) led, joined by existing investors HealthCap, Expon Capital and Sparrow Ventures. The funds will be used to push the commercialisation of HelloBetter’s products in the German market and advance its expansion beyond the DACH region. Hannes Klöpper, cofounder and CEO, HelloBetter, said: “We are excited to receive backing from yet another strong partner, as our category leadership in the field of digital therapeutics for mental health is becoming increasingly more visible.”

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
May 09,2022

Oncological digital therapeutics company Fosanis raises more than $10.5M

Fosanis announced today that it closed a Series A funding round worth more than $10.5 million (€10 million). Berlin, Germany-based Fosanis, which develops prescription digital therapeutics for all oncological indications, picked up investments from existing shareholder Ananada Impact Ventures, as well as new investors Debiopharm Innovation Fund, Ship2B Ventures and Equity Pitcher.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jun 17,2022

Swing Therapeutics scores $10.3M to support fibromyalgia DTx clinical trial

Digital therapeutics startup Swing Therapeutics wrapped up a $10.3 million Series A funding round led by Jazz Venture Partners. Other participants in the raise include Alumni Ventures, AME Cloud Ventures, Asahi Kasei Corporate Ventures, Gaingels, Kicker Ventures, Mana Ventures and Metrodora Ventures. Swing focuses on building and testing a digital therapeutic for fibromyalgia, which causes widespread musculoskeletal pain as well as fatigue, sleep, memory and mood problems and the company was founded in 2019 and launched with $9 million in seed funding.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jul 15,2021

Germany's Dopavision closes €12M Series A round for digital childhood myopia treatment

Berlin-based digital therapeutics company, Dopavision has announced the closing of a €12 million Series A financing round to develop its lead product for childhood myopia. Seventure Partners led the round and was joined by Novartis Pharmaceuticals and the company's existing shareholders, Boehringer Ingelheim Venture Fund and Ababax Health.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jul 19,2021

Chronic condition management startup Sweetch scores $20M

Sweetch, a startup that uses artificial intelligence to help patients manage chronic conditions, today landed $20 million in Series A funding. Entrée Capital led the funding, with participation from Tal Capital, Noaber, Kortex Ventures, Insurtech VC FinTLV Ventures, Philips, OurCrowd and Qure Ventures.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

Blue Note Therapeutics raised an additional $5.2 million in Series A financing, bringing the company’s Series A financing to a total of $31 million. The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

Neuroglee Raises $10M to Develop Virtual Neurology Clinics with Mayo Clinic, Others

Neuroglee, a Boston, MA-based provider of personalized evidence-based digital therapeutics (DTx) and virtual care solutions, today announced it has raised $10M in Series A funding led by OpenSpace Ventures with participation by EDBI. Neuroglee Therapeutics discovers, develops and commercializes personalized evidence-based digital therapeutics (DTx) and virtual care solutions to treat and manage patients with neurodegenerative diseases. In conjunction with the news of the funding round, Neuroglee is announcing plans to move its headquarters to Boston in Q4, as well as a collaboration with Mayo Clinic to co-develop Neuroglee Connect™, a novel clinical care program that will be based on Mayo Clinic’s Healthy Action to Benefit Independence & Thinking® (HABIT).

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 01,2021

Blue Note Therapeutics Raises $26.25 Million in Series A Financing

Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note’s pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Mar 24,2021

AppliedVR Secures $29 Million in Series a Funding to Make Virtual Reality the Standard of Care for Chronic Pain

AppliedVR, a pioneer advancing the next generation of digital medicine, announced $29 million in series A funding, bringing its total funds raised to date to $35 million. The round, which includes key investors F-Prime Capital, JAZZ Venture Partners, Sway Ventures, GSR Ventures, Magnetic Ventures and Cedars-Sinai, will fuel the company’s growth as it pursues full FDA approval over the next year.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Dec 07,2021

Limbix Raises $15 Million in Series A2 Financing

Today, Limbix, a prescription digital therapeutic company developing treatments for adolescent mental health disorders, announced it has raised $15 million in Series A2 financing from both existing and new investors, bringing total funding to date to $31 million. The round was led by GSR Ventures, with participation from existing investors Digital Garage, Storm Ventures, Bixink and DN Capital. Capital raised in the financing will be used by Limbix for commercialization efforts and to double its staff to approximately 60 employees by Q2, 2022. With an expanded product and research team, Limbix plans to accelerate the development and testing of new digital therapeutics targeting other common adolescent mental health disorders.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Subscribe to SERIES A